Infusion sites have an important role to play in the quick administration of COVID-19 monoclonal antibody rehabs to patients adhering to a COVID-19 medical diagnosis. Bamlanivimab/etesevimab and casirivimab/imdevimab are monoclonal antibody therapeutics that have received Emergency Use Authorization from the U. S. Food and Drug Administration. The EUA calls for administration of therapy as soon as possible after a confirmed positive test result and within 10 days of symptom onset. Infusion sites have to facilitate a rapid turn-around time in between COVID-19 diagnosis and therapy with monoclonal antibody therapeutics for the products to be efficient.
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions
** If you believe that content on the Plex is summarised improperly, please, contact us, and we will get rid of it quickly; please, send an email with a brief explanation.